| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 86 | 2025 | 571 | 10.220 |
Why?
|
| Staphylococcus aureus | 65 | 2024 | 483 | 8.130 |
Why?
|
| Pneumococcal Infections | 52 | 2025 | 281 | 7.010 |
Why?
|
| Streptococcus pneumoniae | 67 | 2026 | 389 | 6.300 |
Why?
|
| Community-Acquired Infections | 45 | 2024 | 254 | 6.140 |
Why?
|
| Anti-Bacterial Agents | 122 | 2026 | 2596 | 4.820 |
Why?
|
| Osteomyelitis | 27 | 2024 | 209 | 4.240 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 37 | 2025 | 235 | 4.190 |
Why?
|
| Bacteremia | 40 | 2025 | 446 | 3.540 |
Why?
|
| Microbial Sensitivity Tests | 73 | 2026 | 859 | 3.370 |
Why?
|
| Pneumococcal Vaccines | 22 | 2025 | 174 | 2.720 |
Why?
|
| Hospitals, Pediatric | 21 | 2025 | 808 | 2.580 |
Why?
|
| Infant | 167 | 2026 | 13352 | 2.160 |
Why?
|
| Methicillin Resistance | 22 | 2017 | 116 | 2.160 |
Why?
|
| Child, Preschool | 177 | 2026 | 15110 | 2.120 |
Why?
|
| Soft Tissue Infections | 11 | 2024 | 90 | 2.040 |
Why?
|
| Child | 206 | 2026 | 26341 | 2.000 |
Why?
|
| Meningitis, Bacterial | 18 | 2022 | 98 | 1.980 |
Why?
|
| Arthritis, Infectious | 11 | 2025 | 65 | 1.870 |
Why?
|
| Penicillins | 16 | 2024 | 154 | 1.730 |
Why?
|
| Cross Infection | 10 | 2019 | 339 | 1.620 |
Why?
|
| Haemophilus influenzae | 32 | 2025 | 134 | 1.510 |
Why?
|
| Penicillin Resistance | 23 | 2024 | 81 | 1.460 |
Why?
|
| Meningococcal Infections | 4 | 2019 | 20 | 1.450 |
Why?
|
| Vancomycin | 20 | 2023 | 226 | 1.320 |
Why?
|
| Otitis Media | 16 | 2024 | 88 | 1.310 |
Why?
|
| Meningitis, Pneumococcal | 17 | 2015 | 42 | 1.290 |
Why?
|
| Oxazolidinones | 10 | 2010 | 32 | 1.280 |
Why?
|
| Humans | 313 | 2026 | 131163 | 1.270 |
Why?
|
| Acetamides | 10 | 2010 | 43 | 1.270 |
Why?
|
| Neisseria meningitidis, Serogroup B | 3 | 2019 | 7 | 1.200 |
Why?
|
| Meningitis, Haemophilus | 19 | 2009 | 34 | 1.140 |
Why?
|
| Pneumonia, Pneumococcal | 8 | 2026 | 88 | 1.120 |
Why?
|
| Haemophilus Infections | 19 | 2025 | 97 | 1.120 |
Why?
|
| Serotyping | 27 | 2026 | 170 | 1.110 |
Why?
|
| Communicable Diseases | 3 | 2022 | 155 | 1.090 |
Why?
|
| Infant, Newborn | 75 | 2025 | 8635 | 1.070 |
Why?
|
| Mastoiditis | 4 | 2024 | 33 | 1.060 |
Why?
|
| Population Surveillance | 8 | 2018 | 396 | 1.060 |
Why?
|
| Adolescent | 92 | 2026 | 20987 | 1.050 |
Why?
|
| Meningococcal Vaccines | 4 | 2018 | 30 | 1.050 |
Why?
|
| Anti-Infective Agents | 10 | 2023 | 266 | 1.050 |
Why?
|
| Coinfection | 3 | 2021 | 187 | 1.030 |
Why?
|
| Staphylococcal Skin Infections | 6 | 2024 | 37 | 1.020 |
Why?
|
| Cat-Scratch Disease | 5 | 2013 | 32 | 1.020 |
Why?
|
| Male | 157 | 2026 | 64957 | 0.970 |
Why?
|
| Meningitis | 21 | 2017 | 96 | 0.950 |
Why?
|
| Gram-Positive Bacterial Infections | 7 | 2019 | 71 | 0.930 |
Why?
|
| Serogroup | 8 | 2025 | 62 | 0.930 |
Why?
|
| Texas | 30 | 2025 | 3686 | 0.920 |
Why?
|
| Ceftriaxone | 15 | 2016 | 69 | 0.910 |
Why?
|
| Leukocidins | 8 | 2018 | 37 | 0.900 |
Why?
|
| Exotoxins | 8 | 2018 | 44 | 0.900 |
Why?
|
| Female | 149 | 2026 | 70963 | 0.900 |
Why?
|
| Bacterial Infections | 15 | 2025 | 327 | 0.890 |
Why?
|
| Sinusitis | 6 | 2024 | 118 | 0.870 |
Why?
|
| Cephalosporins | 13 | 2022 | 135 | 0.870 |
Why?
|
| Drug Resistance, Bacterial | 16 | 2017 | 401 | 0.840 |
Why?
|
| Streptococcal Infections | 11 | 2024 | 254 | 0.830 |
Why?
|
| Clindamycin | 9 | 2022 | 40 | 0.800 |
Why?
|
| Dexamethasone | 12 | 2009 | 250 | 0.760 |
Why?
|
| Retrospective Studies | 58 | 2026 | 17753 | 0.760 |
Why?
|
| Prospective Studies | 35 | 2025 | 6459 | 0.740 |
Why?
|
| Anti-Infective Agents, Local | 4 | 2019 | 68 | 0.730 |
Why?
|
| Bacterial Toxins | 8 | 2018 | 170 | 0.680 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 10 | 2019 | 89 | 0.660 |
Why?
|
| Antibodies, Bacterial | 11 | 2012 | 406 | 0.660 |
Why?
|
| Splenic Diseases | 4 | 2008 | 28 | 0.650 |
Why?
|
| Liver Abscess | 5 | 2016 | 13 | 0.630 |
Why?
|
| Multilocus Sequence Typing | 9 | 2024 | 63 | 0.620 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 3 | 2004 | 16 | 0.600 |
Why?
|
| Chlorhexidine | 3 | 2017 | 48 | 0.590 |
Why?
|
| Pneumonia | 5 | 2018 | 341 | 0.590 |
Why?
|
| United States | 39 | 2026 | 12072 | 0.580 |
Why?
|
| Head | 1 | 2019 | 111 | 0.570 |
Why?
|
| Neck | 1 | 2019 | 140 | 0.560 |
Why?
|
| Bacterial Typing Techniques | 7 | 2021 | 97 | 0.550 |
Why?
|
| Fever | 7 | 2015 | 312 | 0.530 |
Why?
|
| Vaccines, Conjugate | 8 | 2023 | 80 | 0.520 |
Why?
|
| Meningitis, Meningococcal | 7 | 2013 | 14 | 0.520 |
Why?
|
| Immunocompromised Host | 6 | 2019 | 315 | 0.510 |
Why?
|
| Gram-Positive Bacteria | 4 | 2009 | 44 | 0.500 |
Why?
|
| Rifampin | 8 | 2008 | 128 | 0.500 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2009 | 45 | 0.500 |
Why?
|
| Acute Disease | 15 | 2025 | 1153 | 0.500 |
Why?
|
| Treatment Outcome | 33 | 2022 | 12936 | 0.490 |
Why?
|
| Ear, Middle | 3 | 2015 | 24 | 0.490 |
Why?
|
| Sodium Hypochlorite | 2 | 2013 | 8 | 0.480 |
Why?
|
| Baths | 2 | 2013 | 14 | 0.470 |
Why?
|
| Haemophilus Vaccines | 6 | 1997 | 33 | 0.470 |
Why?
|
| Bartonella henselae | 2 | 2008 | 19 | 0.470 |
Why?
|
| Drug Therapy, Combination | 18 | 2009 | 1173 | 0.470 |
Why?
|
| Retropharyngeal Abscess | 1 | 2015 | 7 | 0.450 |
Why?
|
| Incidence | 17 | 2026 | 3360 | 0.440 |
Why?
|
| Mastoid | 1 | 2015 | 25 | 0.440 |
Why?
|
| Neutrophils | 8 | 2013 | 371 | 0.430 |
Why?
|
| Methicillin | 11 | 2023 | 43 | 0.430 |
Why?
|
| Bacteria | 6 | 2019 | 521 | 0.410 |
Why?
|
| Cellulitis | 5 | 2011 | 63 | 0.410 |
Why?
|
| Vaccines | 1 | 2019 | 388 | 0.400 |
Why?
|
| Disinfection | 1 | 2013 | 24 | 0.400 |
Why?
|
| Drug Resistance, Microbial | 14 | 2004 | 195 | 0.400 |
Why?
|
| Hygiene | 1 | 2013 | 23 | 0.400 |
Why?
|
| Disinfectants | 1 | 2013 | 27 | 0.400 |
Why?
|
| Retinitis | 1 | 2013 | 12 | 0.400 |
Why?
|
| Genital Diseases, Female | 1 | 2013 | 31 | 0.390 |
Why?
|
| Brain Abscess | 6 | 2024 | 54 | 0.390 |
Why?
|
| Carrier State | 2 | 2011 | 80 | 0.380 |
Why?
|
| Influenza, Human | 1 | 2019 | 712 | 0.380 |
Why?
|
| Pseudomonas Infections | 2 | 2009 | 118 | 0.370 |
Why?
|
| Myositis | 2 | 2019 | 84 | 0.370 |
Why?
|
| Streptococcus anginosus | 2 | 2024 | 10 | 0.360 |
Why?
|
| Hospitalization | 8 | 2026 | 1950 | 0.360 |
Why?
|
| Growth Plate | 1 | 2012 | 20 | 0.350 |
Why?
|
| Pneumonia, Bacterial | 4 | 2016 | 78 | 0.350 |
Why?
|
| Abscess | 3 | 2024 | 135 | 0.350 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 17 | 0.340 |
Why?
|
| Bacterial Vaccines | 6 | 2007 | 101 | 0.340 |
Why?
|
| Organ Transplantation | 3 | 2016 | 175 | 0.340 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 1996 | 125 | 0.340 |
Why?
|
| Ampicillin | 12 | 2004 | 59 | 0.330 |
Why?
|
| Adhesins, Bacterial | 4 | 2020 | 74 | 0.330 |
Why?
|
| Linezolid | 10 | 2010 | 25 | 0.330 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2004 | 102 | 0.330 |
Why?
|
| Chi-Square Distribution | 7 | 2013 | 563 | 0.310 |
Why?
|
| Neutropenia | 3 | 2009 | 209 | 0.310 |
Why?
|
| Staphylococcus | 6 | 2019 | 68 | 0.310 |
Why?
|
| Liver Diseases | 2 | 2008 | 385 | 0.310 |
Why?
|
| Mupirocin | 3 | 2015 | 20 | 0.300 |
Why?
|
| Cefotaxime | 10 | 2002 | 37 | 0.300 |
Why?
|
| Cephalosporin Resistance | 5 | 2002 | 17 | 0.300 |
Why?
|
| Citrobacter | 7 | 1992 | 21 | 0.300 |
Why?
|
| Glucocorticoids | 2 | 2009 | 348 | 0.290 |
Why?
|
| Bone Diseases, Infectious | 2 | 2019 | 8 | 0.290 |
Why?
|
| Blister | 1 | 2009 | 18 | 0.290 |
Why?
|
| Salmonella Infections | 2 | 2019 | 29 | 0.290 |
Why?
|
| Skin Diseases, Bacterial | 4 | 2014 | 22 | 0.290 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 5 | 2016 | 157 | 0.280 |
Why?
|
| Anemia, Sickle Cell | 3 | 2019 | 334 | 0.280 |
Why?
|
| Tetanus Toxoid | 3 | 1994 | 48 | 0.270 |
Why?
|
| Toxocariasis | 1 | 2008 | 29 | 0.270 |
Why?
|
| Catheter-Related Infections | 1 | 2010 | 146 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 265 | 0.270 |
Why?
|
| Young Adult | 12 | 2019 | 10103 | 0.270 |
Why?
|
| Ascites | 1 | 2008 | 99 | 0.260 |
Why?
|
| Recurrence | 8 | 2016 | 1489 | 0.260 |
Why?
|
| Cerebral Ventriculitis | 2 | 2017 | 16 | 0.260 |
Why?
|
| DNA, Bacterial | 6 | 2021 | 481 | 0.260 |
Why?
|
| Candidiasis | 3 | 1996 | 134 | 0.260 |
Why?
|
| Eosinophils | 1 | 2008 | 122 | 0.260 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 197 | 0.260 |
Why?
|
| Respiratory Tract Infections | 4 | 2001 | 298 | 0.250 |
Why?
|
| Polymerase Chain Reaction | 7 | 2011 | 1447 | 0.250 |
Why?
|
| Moxalactam | 9 | 1988 | 21 | 0.250 |
Why?
|
| Virulence Factors | 4 | 2018 | 180 | 0.250 |
Why?
|
| Molecular Epidemiology | 6 | 2020 | 139 | 0.250 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 57 | 0.240 |
Why?
|
| Whooping Cough | 2 | 2025 | 65 | 0.240 |
Why?
|
| Otitis Media with Effusion | 2 | 2004 | 30 | 0.240 |
Why?
|
| Endocarditis, Bacterial | 2 | 2024 | 128 | 0.240 |
Why?
|
| Chloramphenicol | 8 | 1993 | 25 | 0.240 |
Why?
|
| Immunization Schedule | 3 | 2019 | 111 | 0.230 |
Why?
|
| Child, Hospitalized | 3 | 2026 | 76 | 0.230 |
Why?
|
| Enterobacteriaceae Infections | 4 | 1990 | 60 | 0.230 |
Why?
|
| Sepsis | 9 | 2015 | 493 | 0.230 |
Why?
|
| Spleen | 3 | 2002 | 258 | 0.230 |
Why?
|
| Leukocyte Count | 8 | 2013 | 246 | 0.230 |
Why?
|
| Measles | 1 | 2025 | 39 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2012 | 3763 | 0.220 |
Why?
|
| Pediatrics | 2 | 2013 | 1252 | 0.210 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 164 | 0.210 |
Why?
|
| DNA Fingerprinting | 4 | 2010 | 106 | 0.210 |
Why?
|
| Exudates and Transudates | 1 | 2004 | 15 | 0.210 |
Why?
|
| Vaccination | 6 | 2025 | 1060 | 0.210 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2006 | 117 | 0.210 |
Why?
|
| beta-Lactams | 1 | 2004 | 56 | 0.200 |
Why?
|
| Penicillin G | 2 | 2023 | 18 | 0.200 |
Why?
|
| Cefadroxil | 1 | 2003 | 1 | 0.200 |
Why?
|
| Azithromycin | 1 | 2004 | 51 | 0.200 |
Why?
|
| Pelvis | 1 | 2024 | 70 | 0.200 |
Why?
|
| Aminoglycosides | 4 | 2018 | 45 | 0.200 |
Why?
|
| Exanthema | 1 | 2004 | 74 | 0.190 |
Why?
|
| Ketolides | 1 | 2003 | 4 | 0.190 |
Why?
|
| Age Factors | 9 | 2020 | 2825 | 0.190 |
Why?
|
| Erythromycin | 1 | 2003 | 20 | 0.190 |
Why?
|
| Salmonella | 2 | 2019 | 29 | 0.190 |
Why?
|
| Risk Factors | 14 | 2020 | 11074 | 0.190 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 274 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 1 | 2004 | 223 | 0.190 |
Why?
|
| Genotype | 7 | 2018 | 2595 | 0.190 |
Why?
|
| Prognosis | 7 | 2013 | 4886 | 0.190 |
Why?
|
| Frontal Sinusitis | 1 | 2002 | 4 | 0.190 |
Why?
|
| Monte Carlo Method | 1 | 2023 | 98 | 0.180 |
Why?
|
| E-Selectin | 2 | 2004 | 38 | 0.180 |
Why?
|
| Lung Diseases | 2 | 2009 | 398 | 0.180 |
Why?
|
| Epidural Abscess | 1 | 2002 | 11 | 0.180 |
Why?
|
| Endothelium, Vascular | 2 | 1997 | 468 | 0.180 |
Why?
|
| Catheterization, Central Venous | 2 | 1994 | 143 | 0.180 |
Why?
|
| Bacterial Proteins | 7 | 2019 | 953 | 0.180 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2003 | 78 | 0.180 |
Why?
|
| Adult | 24 | 2025 | 31282 | 0.180 |
Why?
|
| Statistics, Nonparametric | 5 | 2013 | 423 | 0.180 |
Why?
|
| Amoxicillin | 1 | 2023 | 116 | 0.180 |
Why?
|
| Arthritis | 2 | 2019 | 85 | 0.180 |
Why?
|
| beta-Lactamases | 1 | 2024 | 211 | 0.180 |
Why?
|
| Splenectomy | 1 | 2002 | 61 | 0.180 |
Why?
|
| Bacterial Outer Membrane Proteins | 5 | 1990 | 116 | 0.170 |
Why?
|
| Genes, Bacterial | 2 | 2020 | 215 | 0.170 |
Why?
|
| Drug Monitoring | 1 | 2024 | 292 | 0.170 |
Why?
|
| Macrophage-1 Antigen | 2 | 2001 | 21 | 0.170 |
Why?
|
| Neisseria meningitidis | 3 | 2013 | 20 | 0.170 |
Why?
|
| Time Factors | 7 | 2015 | 6196 | 0.170 |
Why?
|
| Meningitis, Aseptic | 1 | 2001 | 12 | 0.170 |
Why?
|
| Lung Abscess | 3 | 2002 | 15 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2008 | 2065 | 0.170 |
Why?
|
| Facial Dermatoses | 1 | 2000 | 8 | 0.160 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2000 | 9 | 0.160 |
Why?
|
| Deafness | 5 | 1998 | 77 | 0.160 |
Why?
|
| Drug Approval | 1 | 2021 | 48 | 0.160 |
Why?
|
| Cytarabine | 1 | 2001 | 100 | 0.160 |
Why?
|
| Cefazolin | 1 | 2020 | 19 | 0.160 |
Why?
|
| Immunization, Passive | 1 | 2001 | 120 | 0.160 |
Why?
|
| Genome, Bacterial | 1 | 2001 | 200 | 0.160 |
Why?
|
| Blood Culture | 1 | 2020 | 44 | 0.160 |
Why?
|
| Labyrinthitis | 3 | 1991 | 10 | 0.160 |
Why?
|
| Staphylococcal Scalded Skin Syndrome | 1 | 2020 | 8 | 0.150 |
Why?
|
| Diphtheria Toxoid | 2 | 1990 | 6 | 0.150 |
Why?
|
| Comorbidity | 4 | 2017 | 1595 | 0.150 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 14 | 0.150 |
Why?
|
| Abdominal Abscess | 2 | 1998 | 23 | 0.150 |
Why?
|
| Escherichia coli Infections | 5 | 1995 | 198 | 0.150 |
Why?
|
| Polysaccharides, Bacterial | 5 | 1992 | 65 | 0.150 |
Why?
|
| Biofilms | 1 | 2020 | 96 | 0.150 |
Why?
|
| Genes, MDR | 1 | 2019 | 6 | 0.150 |
Why?
|
| Cephamycins | 4 | 1982 | 11 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2022 | 413 | 0.150 |
Why?
|
| Brain Diseases | 2 | 1995 | 299 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 195 | 0.140 |
Why?
|
| Cerebrospinal Fluid Shunts | 2 | 2018 | 79 | 0.140 |
Why?
|
| Prevalence | 8 | 2018 | 2701 | 0.140 |
Why?
|
| Echocardiography | 1 | 2024 | 1125 | 0.140 |
Why?
|
| Typhoid Fever | 1 | 1998 | 17 | 0.140 |
Why?
|
| Flavobacterium | 1 | 1998 | 4 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2022 | 564 | 0.140 |
Why?
|
| Orbital Cellulitis | 1 | 2018 | 15 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 589 | 0.140 |
Why?
|
| Ibuprofen | 1 | 1998 | 41 | 0.140 |
Why?
|
| Pandemics | 2 | 2022 | 1118 | 0.140 |
Why?
|
| Bacterial Adhesion | 4 | 1993 | 104 | 0.140 |
Why?
|
| Hearing Loss, Bilateral | 2 | 1997 | 16 | 0.140 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 5196 | 0.140 |
Why?
|
| Labyrinth Diseases | 2 | 1989 | 6 | 0.130 |
Why?
|
| Prostheses and Implants | 1 | 2019 | 146 | 0.130 |
Why?
|
| Cytokines | 1 | 2004 | 1339 | 0.130 |
Why?
|
| Administration, Oral | 7 | 2018 | 711 | 0.130 |
Why?
|
| Immunoglobulin G | 3 | 2012 | 786 | 0.130 |
Why?
|
| Hearing Loss | 3 | 2009 | 204 | 0.130 |
Why?
|
| Bacterial Capsules | 3 | 2016 | 42 | 0.130 |
Why?
|
| Drainage | 3 | 2010 | 250 | 0.130 |
Why?
|
| P-Selectin | 1 | 1997 | 69 | 0.130 |
Why?
|
| Bacteriological Techniques | 2 | 2016 | 88 | 0.130 |
Why?
|
| Hospitals | 2 | 2011 | 435 | 0.130 |
Why?
|
| Nervous System Diseases | 3 | 1995 | 395 | 0.130 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1998 | 78 | 0.130 |
Why?
|
| Acetaminophen | 1 | 1998 | 100 | 0.130 |
Why?
|
| Prostatic Diseases | 1 | 2017 | 12 | 0.130 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2018 | 124 | 0.130 |
Why?
|
| Age Distribution | 4 | 2010 | 422 | 0.130 |
Why?
|
| Virulence | 4 | 2005 | 268 | 0.120 |
Why?
|
| Diarrhea | 1 | 2018 | 301 | 0.120 |
Why?
|
| Students | 1 | 2019 | 250 | 0.120 |
Why?
|
| Animals | 20 | 2019 | 33912 | 0.120 |
Why?
|
| Oxazoles | 1 | 1996 | 21 | 0.120 |
Why?
|
| Brucella melitensis | 1 | 1996 | 8 | 0.120 |
Why?
|
| Brucellosis | 1 | 1996 | 19 | 0.120 |
Why?
|
| Probability | 4 | 2005 | 306 | 0.120 |
Why?
|
| Enterococcus | 2 | 2019 | 30 | 0.120 |
Why?
|
| Penicillanic Acid | 1 | 2015 | 10 | 0.110 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 79 | 0.110 |
Why?
|
| Mice, Mutant Strains | 4 | 1997 | 356 | 0.110 |
Why?
|
| Whipple Disease | 1 | 1995 | 5 | 0.110 |
Why?
|
| Electronic Health Records | 2 | 2019 | 844 | 0.110 |
Why?
|
| Streptococcus | 2 | 2015 | 64 | 0.110 |
Why?
|
| Bacteria, Anaerobic | 1 | 1995 | 8 | 0.110 |
Why?
|
| Clostridium Infections | 1 | 2018 | 250 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 398 | 0.110 |
Why?
|
| Disease Management | 3 | 2019 | 558 | 0.110 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 69 | 0.110 |
Why?
|
| Prostate | 1 | 2017 | 404 | 0.110 |
Why?
|
| Severity of Illness Index | 6 | 2010 | 3061 | 0.110 |
Why?
|
| Staphylococcus epidermidis | 2 | 1993 | 39 | 0.100 |
Why?
|
| Cluster Analysis | 3 | 2011 | 414 | 0.100 |
Why?
|
| Infection Control | 1 | 2015 | 158 | 0.100 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1994 | 16 | 0.100 |
Why?
|
| Cats | 2 | 2008 | 117 | 0.100 |
Why?
|
| Risk Assessment | 6 | 2012 | 3711 | 0.100 |
Why?
|
| Rhizopus | 1 | 1993 | 10 | 0.100 |
Why?
|
| Intestines | 1 | 1998 | 587 | 0.100 |
Why?
|
| Tetanus | 1 | 1994 | 23 | 0.100 |
Why?
|
| Hearing Loss, Sensorineural | 4 | 1995 | 157 | 0.100 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 732 | 0.100 |
Why?
|
| Necrosis | 3 | 2002 | 192 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 52 | 0.100 |
Why?
|
| Eczema | 1 | 2013 | 35 | 0.100 |
Why?
|
| Infusions, Intravenous | 5 | 2016 | 531 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2009 | 46 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 2 | 1997 | 981 | 0.100 |
Why?
|
| Mucormycosis | 1 | 1993 | 31 | 0.100 |
Why?
|
| Lung Transplantation | 2 | 2009 | 363 | 0.100 |
Why?
|
| Single-Blind Method | 1 | 2013 | 238 | 0.100 |
Why?
|
| Nasal Cavity | 2 | 2011 | 56 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2001 | 895 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 333 | 0.090 |
Why?
|
| Ticarcillin | 2 | 2009 | 8 | 0.090 |
Why?
|
| Gentamicins | 4 | 2009 | 88 | 0.090 |
Why?
|
| Drug Synergism | 4 | 1998 | 237 | 0.090 |
Why?
|
| Kingella kingae | 2 | 2025 | 8 | 0.090 |
Why?
|
| Clinical Trials as Topic | 7 | 2002 | 1129 | 0.090 |
Why?
|
| Down Syndrome | 1 | 2015 | 233 | 0.090 |
Why?
|
| Fimbriae, Bacterial | 6 | 1992 | 39 | 0.090 |
Why?
|
| Antibodies, Catalytic | 1 | 2012 | 7 | 0.090 |
Why?
|
| Cefuroxime | 4 | 2001 | 15 | 0.090 |
Why?
|
| Epidemiologic Studies | 2 | 2002 | 40 | 0.090 |
Why?
|
| Pleural Effusion | 3 | 2004 | 103 | 0.090 |
Why?
|
| Outpatients | 2 | 2024 | 262 | 0.090 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 46 | 0.090 |
Why?
|
| Fractures, Spontaneous | 1 | 2012 | 19 | 0.090 |
Why?
|
| Empyema, Pleural | 2 | 2004 | 26 | 0.090 |
Why?
|
| Radiography | 5 | 2004 | 743 | 0.090 |
Why?
|
| Career Choice | 1 | 2013 | 166 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 32 | 0.090 |
Why?
|
| Drug Resistance | 2 | 2021 | 242 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2023 | 1618 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 2085 | 0.080 |
Why?
|
| Rats | 8 | 1997 | 3370 | 0.080 |
Why?
|
| Proteolysis | 1 | 2012 | 200 | 0.080 |
Why?
|
| Encephalitis | 2 | 2008 | 122 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2012 | 197 | 0.080 |
Why?
|
| Cystic Fibrosis | 2 | 2009 | 268 | 0.080 |
Why?
|
| Virus Diseases | 2 | 2011 | 285 | 0.080 |
Why?
|
| Synovial Fluid | 1 | 2009 | 15 | 0.080 |
Why?
|
| Public Health Surveillance | 2 | 2020 | 43 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 1988 | 299 | 0.080 |
Why?
|
| Vaccines, Synthetic | 1 | 1990 | 325 | 0.070 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2025 | 514 | 0.070 |
Why?
|
| Clavulanic Acid | 1 | 2009 | 7 | 0.070 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2009 | 25 | 0.070 |
Why?
|
| Infant, Premature | 4 | 2007 | 872 | 0.070 |
Why?
|
| Infant, Low Birth Weight | 4 | 1993 | 172 | 0.070 |
Why?
|
| Anemia | 2 | 2003 | 354 | 0.070 |
Why?
|
| Cochlea | 1 | 1989 | 85 | 0.070 |
Why?
|
| Thigh | 1 | 2009 | 50 | 0.070 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2008 | 3 | 0.070 |
Why?
|
| Diagnosis, Differential | 5 | 2011 | 1882 | 0.070 |
Why?
|
| Leukocytosis | 2 | 2000 | 46 | 0.070 |
Why?
|
| Albendazole | 1 | 2008 | 26 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 474 | 0.070 |
Why?
|
| Toxocara | 1 | 2008 | 16 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2009 | 352 | 0.070 |
Why?
|
| Temporal Bone | 1 | 2008 | 38 | 0.070 |
Why?
|
| Vasopressins | 2 | 1978 | 42 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 96 | 0.070 |
Why?
|
| Kinetics | 7 | 1992 | 1088 | 0.070 |
Why?
|
| Anthelmintics | 1 | 2008 | 56 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 1280 | 0.070 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 2 | 2006 | 25 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1378 | 0.070 |
Why?
|
| Coagulase | 3 | 2018 | 22 | 0.070 |
Why?
|
| Organophosphonates | 1 | 2007 | 21 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2904 | 0.070 |
Why?
|
| Cytosine | 1 | 2007 | 56 | 0.060 |
Why?
|
| Complement Factor H | 1 | 2007 | 24 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2008 | 217 | 0.060 |
Why?
|
| Adenovirus Infections, Human | 1 | 2007 | 60 | 0.060 |
Why?
|
| Receptors, Complement | 1 | 2007 | 34 | 0.060 |
Why?
|
| Sex Distribution | 2 | 2010 | 318 | 0.060 |
Why?
|
| Amphotericin B | 1 | 1987 | 89 | 0.060 |
Why?
|
| Paresis | 1 | 1986 | 32 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2016 | 5063 | 0.060 |
Why?
|
| Nasopharynx | 2 | 1990 | 88 | 0.060 |
Why?
|
| Antigens, Bacterial | 3 | 2007 | 319 | 0.060 |
Why?
|
| Fever of Unknown Origin | 2 | 1996 | 44 | 0.060 |
Why?
|
| Leukocytes | 2 | 1997 | 205 | 0.060 |
Why?
|
| Haemophilus parainfluenzae | 1 | 2005 | 11 | 0.060 |
Why?
|
| Morbidity | 1 | 2006 | 256 | 0.060 |
Why?
|
| Africa | 1 | 2006 | 135 | 0.060 |
Why?
|
| Pertussis Vaccine | 1 | 2025 | 27 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2005 | 46 | 0.060 |
Why?
|
| Measles Vaccine | 1 | 2025 | 11 | 0.060 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 180 | 0.050 |
Why?
|
| Encephalitis, St. Louis | 1 | 2004 | 24 | 0.050 |
Why?
|
| Infant, Premature, Diseases | 1 | 1987 | 255 | 0.050 |
Why?
|
| Thrombocytopenia | 2 | 2003 | 223 | 0.050 |
Why?
|
| Hearing Loss, Central | 1 | 1984 | 3 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2007 | 807 | 0.050 |
Why?
|
| Blood Platelets | 1 | 1987 | 313 | 0.050 |
Why?
|
| Middle Aged | 6 | 2015 | 28601 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2001 | 1483 | 0.050 |
Why?
|
| Etoposide | 1 | 2004 | 112 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3359 | 0.050 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2005 | 71 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 1240 | 0.050 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2004 | 51 | 0.050 |
Why?
|
| Lactams | 1 | 2004 | 23 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 182 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 105 | 0.050 |
Why?
|
| Musculoskeletal Diseases | 1 | 2004 | 57 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2025 | 166 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 72 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2004 | 132 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2004 | 236 | 0.050 |
Why?
|
| Latin America | 1 | 2003 | 110 | 0.050 |
Why?
|
| Subdural Effusion | 3 | 1992 | 8 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2004 | 96 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2005 | 292 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2004 | 351 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2005 | 319 | 0.050 |
Why?
|
| Global Health | 2 | 2021 | 626 | 0.050 |
Why?
|
| Nafcillin | 2 | 1982 | 13 | 0.050 |
Why?
|
| Cell Movement | 2 | 1997 | 876 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 272 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2013 | 1223 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 2 | 2000 | 99 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2007 | 351 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2002 | 4697 | 0.050 |
Why?
|
| Length of Stay | 4 | 2018 | 1421 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 1983 | 86 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 1356 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2003 | 148 | 0.050 |
Why?
|
| Empyema | 1 | 2002 | 23 | 0.050 |
Why?
|
| Mice | 6 | 2012 | 18301 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2002 | 33 | 0.050 |
Why?
|
| Microscopy, Electron | 5 | 1992 | 305 | 0.050 |
Why?
|
| Siblings | 1 | 2003 | 201 | 0.040 |
Why?
|
| Age of Onset | 1 | 2003 | 592 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2004 | 412 | 0.040 |
Why?
|
| Pregnancy | 2 | 2025 | 7512 | 0.040 |
Why?
|
| Aspirin | 1 | 2003 | 211 | 0.040 |
Why?
|
| Picornaviridae | 1 | 1981 | 19 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 294 | 0.040 |
Why?
|
| Craniotomy | 1 | 2002 | 102 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2002 | 122 | 0.040 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2001 | 28 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 573 | 0.040 |
Why?
|
| Opsonin Proteins | 1 | 1981 | 19 | 0.040 |
Why?
|
| Thrombosis | 2 | 1997 | 499 | 0.040 |
Why?
|
| Immunologic Techniques | 1 | 1980 | 8 | 0.040 |
Why?
|
| Streptococcus pyogenes | 1 | 2021 | 81 | 0.040 |
Why?
|
| Causality | 1 | 2000 | 89 | 0.040 |
Why?
|
| Species Specificity | 4 | 1998 | 470 | 0.040 |
Why?
|
| Rats, Inbred Strains | 4 | 1991 | 181 | 0.040 |
Why?
|
| Pott Puffy Tumor | 1 | 2020 | 4 | 0.040 |
Why?
|
| Neoplasms | 2 | 2013 | 3016 | 0.040 |
Why?
|
| Mortality | 1 | 2002 | 264 | 0.040 |
Why?
|
| Hearing Disorders | 2 | 1990 | 42 | 0.040 |
Why?
|
| Haemophilus influenzae type b | 1 | 1999 | 6 | 0.040 |
Why?
|
| Ataxia | 1 | 1981 | 160 | 0.040 |
Why?
|
| Central Nervous System Infections | 1 | 2020 | 27 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 3464 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2003 | 1626 | 0.040 |
Why?
|
| HIV Infections | 1 | 2012 | 2049 | 0.040 |
Why?
|
| Cerebrospinal Fluid Proteins | 4 | 1990 | 24 | 0.040 |
Why?
|
| Spinal Puncture | 1 | 1999 | 52 | 0.040 |
Why?
|
| Bone Diseases | 1 | 2019 | 48 | 0.040 |
Why?
|
| Consciousness | 1 | 1999 | 56 | 0.040 |
Why?
|
| Antiporters | 1 | 2019 | 35 | 0.040 |
Why?
|
| Erythema Infectiosum | 1 | 1999 | 5 | 0.040 |
Why?
|
| Flaviviridae | 1 | 1999 | 5 | 0.040 |
Why?
|
| Neisseriaceae Infections | 1 | 1999 | 4 | 0.040 |
Why?
|
| Biopsy | 1 | 2003 | 1239 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 1999 | 10 | 0.040 |
Why?
|
| Ehrlichiosis | 1 | 1999 | 10 | 0.040 |
Why?
|
| Hantavirus Infections | 1 | 1999 | 8 | 0.040 |
Why?
|
| Enterobacter cloacae | 1 | 2018 | 12 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 1999 | 33 | 0.040 |
Why?
|
| Pentosephosphates | 2 | 1992 | 10 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 174 | 0.040 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1999 | 44 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 1999 | 53 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 276 | 0.030 |
Why?
|
| Enema | 1 | 1998 | 45 | 0.030 |
Why?
|
| Hypoxia, Brain | 1 | 1978 | 34 | 0.030 |
Why?
|
| Pneumonia, Aspiration | 1 | 1978 | 17 | 0.030 |
Why?
|
| Amikacin | 3 | 1993 | 23 | 0.030 |
Why?
|
| Hydrocephalus | 2 | 1992 | 245 | 0.030 |
Why?
|
| Judgment | 1 | 2017 | 36 | 0.030 |
Why?
|
| Herpesviridae Infections | 1 | 1999 | 148 | 0.030 |
Why?
|
| Skin | 1 | 2020 | 545 | 0.030 |
Why?
|
| Patient Selection | 1 | 2021 | 729 | 0.030 |
Why?
|
| Fusobacterium | 1 | 2016 | 3 | 0.030 |
Why?
|
| Fusobacterium Infections | 1 | 2016 | 9 | 0.030 |
Why?
|
| Intestinal Obstruction | 1 | 1998 | 86 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 1978 | 98 | 0.030 |
Why?
|
| Patient Admission | 1 | 2018 | 185 | 0.030 |
Why?
|
| Phagocytes | 1 | 1996 | 25 | 0.030 |
Why?
|
| Fungemia | 1 | 1996 | 22 | 0.030 |
Why?
|
| Hypotension | 1 | 1998 | 187 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2018 | 269 | 0.030 |
Why?
|
| Lung | 2 | 2009 | 1535 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 1996 | 20 | 0.030 |
Why?
|
| Oxacillin | 1 | 1995 | 6 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1996 | 38 | 0.030 |
Why?
|
| Mycobacterium chelonae | 1 | 1995 | 4 | 0.030 |
Why?
|
| Epithelium | 3 | 1992 | 335 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1267 | 0.030 |
Why?
|
| beta-Lactam Resistance | 1 | 1996 | 48 | 0.030 |
Why?
|
| Piperacillin | 1 | 2015 | 14 | 0.030 |
Why?
|
| Seizures | 2 | 1992 | 890 | 0.030 |
Why?
|
| Aged | 5 | 2015 | 21025 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 1998 | 401 | 0.030 |
Why?
|
| Bacteria, Aerobic | 1 | 1995 | 1 | 0.030 |
Why?
|
| Brain | 2 | 1996 | 3175 | 0.030 |
Why?
|
| Meninges | 1 | 1995 | 22 | 0.030 |
Why?
|
| Total Quality Management | 1 | 1995 | 22 | 0.030 |
Why?
|
| Eye Infections, Bacterial | 1 | 1995 | 81 | 0.030 |
Why?
|
| Twins | 1 | 2015 | 70 | 0.030 |
Why?
|
| Orbital Diseases | 1 | 1995 | 64 | 0.030 |
Why?
|
| Kidney | 2 | 1996 | 1282 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 721 | 0.030 |
Why?
|
| Ischemia | 1 | 1978 | 359 | 0.030 |
Why?
|
| Random Allocation | 2 | 1988 | 409 | 0.030 |
Why?
|
| Electrophoresis | 1 | 1994 | 32 | 0.030 |
Why?
|
| Animals, Newborn | 4 | 1991 | 1021 | 0.030 |
Why?
|
| Genomics | 1 | 2022 | 1621 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1997 | 1105 | 0.030 |
Why?
|
| Iliac Vein | 1 | 1994 | 24 | 0.030 |
Why?
|
| Diphtheria | 1 | 1994 | 17 | 0.030 |
Why?
|
| Femoral Vein | 1 | 1994 | 42 | 0.030 |
Why?
|
| Diffusion | 1 | 1993 | 56 | 0.030 |
Why?
|
| Diterpenes | 1 | 2014 | 33 | 0.030 |
Why?
|
| Drug Implants | 1 | 1993 | 41 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 98 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 686 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1995 | 387 | 0.020 |
Why?
|
| Meningocele | 1 | 1993 | 18 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2002 | 65 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 1991 | 57 | 0.020 |
Why?
|
| Disease Progression | 1 | 1999 | 2200 | 0.020 |
Why?
|
| Dermoid Cyst | 1 | 1993 | 33 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1986 | 410 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1993 | 318 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 1992 | 61 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1889 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1998 | 1345 | 0.020 |
Why?
|
| Endoscopy | 1 | 2014 | 270 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 210 | 0.020 |
Why?
|
| Cerebral Ventricles | 2 | 1990 | 80 | 0.020 |
Why?
|
| Weight Loss | 1 | 1996 | 538 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 639 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2012 | 20 | 0.020 |
Why?
|
| Base Sequence | 2 | 2007 | 2730 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1993 | 270 | 0.020 |
Why?
|
| Meningoencephalitis | 2 | 2001 | 18 | 0.020 |
Why?
|
| Quinine | 1 | 2012 | 9 | 0.020 |
Why?
|
| Otitis | 1 | 2012 | 11 | 0.020 |
Why?
|
| Klebsiella Infections | 2 | 1990 | 57 | 0.020 |
Why?
|
| Empyema, Subdural | 1 | 1992 | 8 | 0.020 |
Why?
|
| Meningitis, Listeria | 2 | 1988 | 2 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2012 | 57 | 0.020 |
Why?
|
| Genes, Essential | 1 | 2012 | 39 | 0.020 |
Why?
|
| Pentoxifylline | 1 | 1991 | 20 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2003 | 286 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 227 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1996 | 943 | 0.020 |
Why?
|
| Hypothalamic Diseases | 1 | 1992 | 40 | 0.020 |
Why?
|
| Clavulanic Acids | 1 | 1991 | 2 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 975 | 0.020 |
Why?
|
| Premedication | 1 | 1991 | 39 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 101 | 0.020 |
Why?
|
| Enterobacter | 1 | 1990 | 15 | 0.020 |
Why?
|
| Immunization | 2 | 1991 | 269 | 0.020 |
Why?
|
| Vancomycin Resistance | 1 | 2010 | 24 | 0.020 |
Why?
|
| Intestinal Perforation | 1 | 1991 | 51 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 204 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2012 | 377 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 716 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 2 | 1982 | 177 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 1995 | 2326 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 1991 | 158 | 0.020 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 1991 | 62 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 1990 | 118 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Liver | 1 | 1997 | 1796 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 416 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 6797 | 0.020 |
Why?
|
| Arginine Vasopressin | 2 | 1981 | 26 | 0.020 |
Why?
|
| Ceftazidime | 1 | 1990 | 46 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1992 | 301 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 978 | 0.020 |
Why?
|
| Phylogeny | 1 | 2012 | 689 | 0.020 |
Why?
|
| Appendicitis | 1 | 1991 | 132 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1989 | 254 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1990 | 186 | 0.020 |
Why?
|
| Models, Biological | 1 | 1993 | 1371 | 0.020 |
Why?
|
| Sputum | 1 | 2009 | 113 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1991 | 267 | 0.020 |
Why?
|
| Nephritis | 1 | 1988 | 17 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 1988 | 35 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 1988 | 130 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 2395 | 0.020 |
Why?
|
| Complement Pathway, Alternative | 1 | 1987 | 14 | 0.020 |
Why?
|
| Genomic Islands | 1 | 2007 | 29 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 1988 | 29 | 0.020 |
Why?
|
| Streptococcus agalactiae | 1 | 1988 | 106 | 0.020 |
Why?
|
| Phenotype | 3 | 2007 | 4497 | 0.020 |
Why?
|
| Penicillinase | 1 | 1987 | 2 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 152 | 0.020 |
Why?
|
| Hydrolases | 1 | 2007 | 61 | 0.020 |
Why?
|
| Complement Activation | 1 | 1987 | 50 | 0.020 |
Why?
|
| Polysaccharides | 1 | 1988 | 143 | 0.020 |
Why?
|
| Immune Sera | 1 | 2007 | 54 | 0.020 |
Why?
|
| Bleeding Time | 1 | 1987 | 7 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2007 | 198 | 0.020 |
Why?
|
| Molecular Weight | 2 | 1985 | 276 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1992 | 2885 | 0.020 |
Why?
|
| Vaccines, DNA | 1 | 2007 | 44 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 726 | 0.020 |
Why?
|
| Body Fluids | 1 | 1987 | 45 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1992 | 750 | 0.020 |
Why?
|
| Platelet Count | 1 | 1987 | 139 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1987 | 100 | 0.020 |
Why?
|
| Plasmids | 1 | 2007 | 449 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1987 | 358 | 0.020 |
Why?
|
| Organ Culture Techniques | 2 | 2001 | 140 | 0.020 |
Why?
|
| Psychological Tests | 1 | 1986 | 86 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1988 | 1013 | 0.010 |
Why?
|
| Rickettsiaceae Infections | 1 | 1986 | 2 | 0.010 |
Why?
|
| Cochlear Duct | 1 | 1986 | 4 | 0.010 |
Why?
|
| Boutonneuse Fever | 1 | 1986 | 2 | 0.010 |
Why?
|
| Organ of Corti | 1 | 1986 | 25 | 0.010 |
Why?
|
| Luminescent Measurements | 2 | 1987 | 55 | 0.010 |
Why?
|
| Lipopeptides | 1 | 2005 | 37 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2005 | 36 | 0.010 |
Why?
|
| Echinocandins | 1 | 2005 | 42 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2005 | 76 | 0.010 |
Why?
|
| Acyclovir | 1 | 2004 | 49 | 0.010 |
Why?
|
| Encephalitis Virus, St. Louis | 1 | 2004 | 22 | 0.010 |
Why?
|
| Clone Cells | 1 | 2005 | 153 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2007 | 776 | 0.010 |
Why?
|
| Intellectual Disability | 1 | 1992 | 1089 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 645 | 0.010 |
Why?
|
| Audiometry, Evoked Response | 1 | 1984 | 3 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 3 | 1996 | 1295 | 0.010 |
Why?
|
| Evoked Potentials, Auditory | 1 | 1984 | 45 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2002 | 1216 | 0.010 |
Why?
|
| Immune Adherence Reaction | 1 | 1983 | 2 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1993 | 1306 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 237 | 0.010 |
Why?
|
| Brain Stem | 1 | 1984 | 108 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 31 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2002 | 789 | 0.010 |
Why?
|
| Syndrome | 2 | 1993 | 1155 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 1988 | 781 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1988 | 991 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 2 | 1998 | 76 | 0.010 |
Why?
|
| Middle Ear Ventilation | 1 | 2002 | 37 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 1983 | 141 | 0.010 |
Why?
|
| Pharmacogenetics | 1 | 2003 | 201 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1986 | 487 | 0.010 |
Why?
|
| Methods | 2 | 1979 | 95 | 0.010 |
Why?
|
| Mycoses | 1 | 1983 | 110 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 676 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1982 | 239 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1982 | 46 | 0.010 |
Why?
|
| Electronystagmography | 1 | 1981 | 2 | 0.010 |
Why?
|
| Caloric Tests | 1 | 1981 | 7 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 2001 | 28 | 0.010 |
Why?
|
| Picornaviridae Infections | 1 | 1981 | 49 | 0.010 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1980 | 3 | 0.010 |
Why?
|
| Agglutination Tests | 1 | 1980 | 8 | 0.010 |
Why?
|
| Latex Fixation Tests | 1 | 1980 | 4 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1980 | 20 | 0.010 |
Why?
|
| Radioimmunoassay | 2 | 1978 | 82 | 0.010 |
Why?
|
| Biological Assay | 1 | 1981 | 105 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2007 | 1559 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 1981 | 153 | 0.010 |
Why?
|
| Consensus | 1 | 2002 | 512 | 0.010 |
Why?
|
| Inpatients | 1 | 2004 | 562 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1980 | 787 | 0.010 |
Why?
|
| Punctures | 1 | 1978 | 52 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 1692 | 0.010 |
Why?
|
| Needles | 1 | 1978 | 48 | 0.010 |
Why?
|
| Bilirubin | 1 | 1979 | 126 | 0.010 |
Why?
|
| Sulbactam | 1 | 1998 | 6 | 0.010 |
Why?
|
| Tobramycin | 1 | 1998 | 22 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 1176 | 0.010 |
Why?
|
| Asphyxia Neonatorum | 1 | 1978 | 23 | 0.010 |
Why?
|
| Brain Edema | 1 | 1978 | 66 | 0.010 |
Why?
|
| Algorithms | 1 | 2004 | 1680 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1989 | 808 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1978 | 73 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1976 | 115 | 0.010 |
Why?
|
| Cheek | 2 | 1989 | 22 | 0.010 |
Why?
|
| Birth Weight | 2 | 1990 | 347 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1983 | 1590 | 0.010 |
Why?
|
| Vegetables | 1 | 1978 | 267 | 0.010 |
Why?
|
| Eye Injuries, Penetrating | 1 | 1995 | 16 | 0.010 |
Why?
|
| Laparotomy | 1 | 1976 | 138 | 0.010 |
Why?
|
| Clarithromycin | 1 | 1995 | 133 | 0.010 |
Why?
|
| Orbit | 1 | 1995 | 75 | 0.010 |
Why?
|
| Eyelids | 1 | 1995 | 108 | 0.010 |
Why?
|
| Half-Life | 2 | 1985 | 149 | 0.010 |
Why?
|
| Adhesiveness | 2 | 1985 | 13 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 3819 | 0.010 |
Why?
|
| Magnesium Deficiency | 1 | 1972 | 10 | 0.010 |
Why?
|
| Parathyroid Glands | 1 | 1972 | 26 | 0.010 |
Why?
|
| Child Development | 1 | 1995 | 266 | 0.010 |
Why?
|
| Culture Media | 1 | 1992 | 171 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 4738 | 0.010 |
Why?
|
| Ear, Inner | 1 | 1991 | 41 | 0.010 |
Why?
|
| Ampicillin Resistance | 1 | 1991 | 18 | 0.010 |
Why?
|
| Epiglottitis | 1 | 1991 | 13 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1991 | 101 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 1991 | 50 | 0.010 |
Why?
|
| Transillumination | 1 | 1990 | 2 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1990 | 23 | 0.010 |
Why?
|
| Hemadsorption | 1 | 1990 | 2 | 0.000 |
Why?
|
| Appendectomy | 1 | 1991 | 88 | 0.000 |
Why?
|
| Bacteriophage Typing | 1 | 1989 | 2 | 0.000 |
Why?
|
| Neurologic Examination | 1 | 1990 | 185 | 0.000 |
Why?
|
| Intelligence | 1 | 1990 | 103 | 0.000 |
Why?
|
| Mucous Membrane | 1 | 1990 | 95 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1990 | 344 | 0.000 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 1993 | 570 | 0.000 |
Why?
|
| Monocytes | 1 | 1990 | 335 | 0.000 |
Why?
|
| Pyuria | 1 | 1988 | 6 | 0.000 |
Why?
|
| Flow Cytometry | 1 | 1990 | 765 | 0.000 |
Why?
|
| Salmonella typhimurium | 1 | 1987 | 44 | 0.000 |
Why?
|
| Daptomycin | 1 | 1987 | 17 | 0.000 |
Why?
|
| Hemolysis | 1 | 1987 | 86 | 0.000 |
Why?
|
| Bacteriuria | 1 | 1988 | 80 | 0.000 |
Why?
|
| Phagocytosis | 1 | 1987 | 190 | 0.000 |
Why?
|
| Gestational Age | 1 | 1990 | 1224 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1988 | 928 | 0.000 |
Why?
|
| Rickettsia | 1 | 1986 | 17 | 0.000 |
Why?
|
| Glucose | 1 | 1990 | 853 | 0.000 |
Why?
|
| Carbohydrates | 1 | 1985 | 34 | 0.000 |
Why?
|
| Travel | 1 | 1986 | 117 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1985 | 79 | 0.000 |
Why?
|
| beta 2-Microglobulin | 1 | 1984 | 35 | 0.000 |
Why?
|
| Peptides | 1 | 1987 | 708 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1984 | 135 | 0.000 |
Why?
|
| Pharynx | 1 | 1982 | 69 | 0.000 |
Why?
|
| Temperature | 1 | 1982 | 291 | 0.000 |
Why?
|
| Nasal Mucosa | 1 | 1982 | 88 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1982 | 437 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 1988 | 1224 | 0.000 |
Why?
|
| Charcoal | 1 | 1979 | 8 | 0.000 |
Why?
|
| Spectrophotometry | 1 | 1979 | 42 | 0.000 |
Why?
|
| Parathyroid Hormone | 1 | 1972 | 83 | 0.000 |
Why?
|
| Magnesium | 1 | 1972 | 114 | 0.000 |
Why?
|
| Phosphates | 1 | 1972 | 112 | 0.000 |
Why?
|
| Calcium | 1 | 1972 | 1010 | 0.000 |
Why?
|